comparemela.com

Latest Breaking News On - Lees schwartzberg - Page 1 : comparemela.com

Sierra Nevada Forums resume September in Carson City

The Sierra Nevada Forums, in partnership with the American Association of University Women and the League of Women Voters of Northern Nevada will host UNR Innovative Research and Medical Breakthroughs on September 19 at the Brewery Arts Center Performance Hall, 511 W King St in Carson City.

Sierra Nevada Forums resume September in Carson City

The Sierra Nevada Forums, in partnership with the American Association of University Women and the League of Women Voters of Northern Nevada will host UNR Innovative Research and Medical Breakthroughs on September 19 at the Brewery Arts Center Performance Hall, 511 W King St in Carson City.

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer

Estrogen receptor (ER) is present in 85% of all breast cancers, and more than 90% of ER+ positive breast cancers also contain the AR which has been demonstrated to be an important therapeutic target in ER+ breast cancer. Enobosarm is an oral drug that selectively targets the AR in breast cancer without having the unwanted virilizing androgen adverse side effects including facial hair, acne, increase in hematocrit, or liver toxicity, while having potential clinical benefits including increasing muscle and physical function as well addressing cancer treatment induced bone loss and fractures. Enobosarm has extensive nonclinical and clinical experience having been evaluated in 25 separate clinical studies with 2,091 enrolled patients, including three Phase 2 clinical studies in advanced breast cancer. There are also at least two enobosarm investigator-initiated Phase 2 clinical studies in advanced breast cancer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.